Anton Yu Bespalov

Anton Yu Bespalov

Auto-generated profile, based on publicly available information

Anton Yu Bespalov

Exciva

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CEChristoph H. Emmerich
Christoph H. Emmerich
LGLorena Martinez Gamboa
Lorena Martinez Gamboa
MHMartine C. J. Hofmann
Martine C. J. Hofmann
MBMarc Bonin-Andresen
Marc Bonin-Andresen
OAOlga Arbach
Olga Arbach
MPMichael J. Parnham
Michael J. Parnham

1 February 2007 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
IBIrina Belozertseva
Irina Belozertseva
TKT Kos
T Kos
PPP Popik
P Popik
WDW Danysz
W Danysz
ABA Bespalov
A Bespalov

1 March 2010 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
GMGerard J. Marek
Gerard J. Marek
BBBerthold Behl
Berthold Behl
ABAnton Y. Bespalov
Anton Y. Bespalov
GGGerhard Gross
Gerhard Gross
YLYounglim Lee
Younglim Lee
HSHans Schoemaker
Hans Schoemaker
Dopamine D2 receptor blockade has been an obligate mechanism of action present in all medications that effectively treat positive symptoms of schizophrenia (e.g., delusions and hallucinations) and have been approved by regulatory agencies since the 1950s. Blockade of 5-hydroxytrypatmine2A receptors plays a contributory role in the actions of the second generation of antipsychotic drugs, the so-called atypical antipsychotics. Nevertheless, substantial unmet medical needs remain for the treatment of negative symptoms and cognitive dysfunction. Recognition that dissociative anesthetics block the N-methyl-d-aspartate (NMDA) receptor channel has inspired a search for glutamatergic therapeutic mechanisms because ketamine and phencyclidine are known to induce psychotic-like symptoms in healthy volunteers and exacerbate the symptoms of patients with schizophrenia. Current pathophysiological theories of schizophrenia emphasize that hypofunction of NMDA receptors at critical sites in local circuits modulate the function of a given brain region or control projections from one region to another (e.g., hippocampal-cortical or thalamocortical projections). The demonstration that a metabotropic glutamate 2/3 (mGlu2/3) receptor agonist prodrug decreased both positive and negative symptoms of schizophrenia raised hopes that glutamatergic mechanisms may provide therapeutic advantages. In addition to discussing the activation of mGlu2 receptors with mGlu2/3 receptor agonists or mGlu2 receptor positive allosteric modulators (PAMs), we discuss other methods that may potentially modulate circuits with hypofunctional NMDA receptors such as glycine transporter inhibitors and mGlu5 receptor PAMs. The hope is that by modulating glutamatergic neurotransmission, the dysfunctional circuitry of the schizophrenic brain (both local circuits and long-loop pathways) will be improved.

1 January 2005 in Neuropharmacology
Verified
Journal Article
Closed access
ABAnton Y. Bespalov
Anton Y. Bespalov
ODOlga A Dravolina
Olga A Dravolina
ISIlya Sukhanov
Ilya Sukhanov
EZElena Zakharova
Elena Zakharova
EBElena Blokhina
Elena Blokhina
AMAthina Markou
Athina Markou

4 August 2010 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
HHHeinz Hillen
Heinz Hillen
SBStefan Barghorn
Stefan Barghorn
ASAndreas Striebinger
Andreas Striebinger
BLBoris Labkovsky
Boris Labkovsky
RMReinhold Müller
Reinhold Müller
UEUlrich Ebert
Ulrich Ebert
Oligomers of the β-amyloid (Aβ) peptide have been indicated in early neuropathologic changes in Alzheimer's disease. Here, we present a synthetic Aβ20-42oligomer (named globulomer) with a different conformation to monomeric and fibrillar Aβ peptide, enabling the generation of highly Aβ oligomer-specific monoclonal antibodies. The globulomer-derived antibodies specifically detect oligomeric but not monomeric or fibrillar Aβ in various Aβ preparations. The globulomer-specific antibody A-887755 was able to prevent Aβ oligomer binding and dynamin cleavage in primary hippocampal neurons and to reverse globulomer-induced reduced synaptic transmission. In amyloid precursor protein (APP) transgenic mice, vaccination with Aβ globulomer and treatment with A-887755 improved novel object recognition. The cognitive improvement is likely attributable to reversing a deficit in hippocampal synaptic spine density in APP transgenic mice as observed after treatment with A-887755. Our findings demonstrate that selective reduction of Aβ oligomers by immunotherapy is sufficient to normalize cognitive behavior and synaptic deficits in APP transgenic mice.

1 May 2005 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MPMałgorzata Pietraszek
Małgorzata Pietraszek
ISIlya Sukhanov
Ilya Sukhanov
PMPiotr Maciejak
Piotr Maciejak
JSJanusz Szyndler
Janusz Szyndler
AGAndreas Gravius
Andreas Gravius
WDWojciech Danysz
Wojciech Danysz